Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-EphA2 antibody + IR700
- Development stage
- Preclinical
- Lead developer
- Absolute Antibody
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Anti-EphA2 antibody + IR700** is a targeted drug conjugate used in cancer photoimmunotherapy consisting of a monoclonal antibody against the EphA2 receptor conjugated with the near-infrared (NIR) phthalocyanine dye IRDye 700DX (IR700). The conjugate binds specifically to EphA2-expressing tumor cells; upon NIR light irradiation at 690 nm, the IR700 dye is activated, inducing rapid, localized cytotoxicity toward antibody-bound cells. This modality allows selective cancer cell killing with minimal effects on surrounding tissues. Anti-EphA2-IR700 has demonstrated in vitro and in vivo anti-tumor activity in preclinical cancer models, including colorectal cancer. Its mechanism is highly dependent on both conjugate binding and applied NIR light; systemic administration without illumination does not result in cytotoxicity[1].
- Other names
- anti-EphA2-IR700 conjugateanti-EphA-2-IR700 conjugateanti-EphA 2-IR700 conjugateanti-EphA2-IRDye 700DX conjugateanti-EphA-2-IRDye 700DX conjugateanti-EphA 2-IRDye 700DX conjugate
02
Targets
EPHA2 (Ephrin type-A receptor 2)
Beyond the preview
Go deeper on anti-EphA2 antibody + IR700.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-EphA2 antibody + IR700.